Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Rating Lowered by Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 1.0%

BDRX opened at $0.62 on Monday. Biodexa Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $19.30. The company has a fifty day moving average of $1.18 and a two-hundred day moving average of $3.81.

Biodexa Pharmaceuticals shares are going to reverse split on the morning of Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its quarterly earnings results on Friday, March 27th. The company reported $0.70 earnings per share (EPS) for the quarter. Sell-side analysts predict that Biodexa Pharmaceuticals will post -1.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.